CASE REPORT

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy

Takafumi Aritomi, Takashi Kido, Kazuhisa Nakano, Yurie Satoh, Shingo Noguchi, Takanobu Jotatsu, Tetsuya Hanaka, Minoru Satoh, Yoshiya Tanaka and Kazuhiro Yatera

Abstract:
We herein report a 63-year-old woman with small-cell lung cancer (SCLC) who developed dermatomyositis (DM) after initial chemoradiotherapy despite tumor reduction. Serum anti-transcriptional intermediary factor (TIF) 1γ antibody was detected before the development of DM, and its levels increased over time. She died five months after the diagnosis of SCLC. Anti-TIF1γ antibody is known to be a marker for cancer-associated DM (CAM); however, the present case indicates that the antibody can be found in cancer patients without DM. This case is also unusual, as DM developed later despite successful chemoradiotherapy.

Key words: anti-transcriptional intermediary factor 1 γ antibody, chemoradiotherapy, dermatomyositis, autoantibody, small-cell lung cancer

Introduction

Dermatomyositis (DM) and polymyositis (PM) are systemic autoimmune rheumatic diseases characterized by proximal muscle weakness, myalgia, and characteristic skin rash. An increased risk of cancer in DM/PM, particularly DM, has been well described for many years. In recent years, anti-transcriptional intermediary factor 1 γ (TIF1γ) antibody was shown to be strongly associated with cancer-associated DM/PM (CAM), as confirmed by a meta-analysis (1-4).

We herein report a rare case of small-cell lung cancer (SCLC) in which anti-TIF1γ antibody was detected prior to the appearance of DM. The patient developed muscle weakness, elevated muscle enzymes, and typical skin rash of DM after initial chemoradiotherapy for SCLC despite tumor reduction.

Case Report

A 63-year-old woman with a smoking history of 20 pack-years, alcoholic liver injury, and hypertension had onset of cough and hoarseness. A chest X-ray showed left hilar enlargement, and chest computed tomography (CT) revealed a 5-cm mass in the left upper lobe and 8-cm diameter mediastinal lymph node swelling (Fig. 1a). The levels of serum tumor markers, such as pro-gastrin-releasing peptide (pro-GRP) (4,490 pg/mL; normal range, <46 pg/mL) and nerve-specific enolase (NSE) (138 ng/mL; normal range, <10 ng/mL), were elevated. The serum levels of aspartate transferase (35 IU/L) and creatine kinase (57 U/L) were within normal limits, while those of lactate dehydrogenase (286 IU/L) and C-reactive protein (0.57 mg/dL) were slightly increased. Pathology of biopsy specimens obtained from the mediastinal lymph node and left main tumor by flexible bronchoscopy revealed SCLC,
and a systemic image analysis showed no distant metastasis; thus, she was diagnosed with limited stage SCLC. Systemic chemoradiotherapy with carboplatin plus etoposide was initiated, which led to a significant reduction in the tumor size in the lung and mediastinal lymph node on chest X-ray and a decrease in the levels of serum tumor markers. She was discharged without any clinical signs or symptoms of PM/DM at 27 days after chemotherapy. However, a week later, general malaise; facial edema; erythema on the hand, back, and body; proximal myalgia; muscle weakness; and dysphagia developed, and she was urgently readmitted to our hospital.

At the time of readmission, she was alert, and physical findings were as follows: height 146.5 cm, body weight 47.5 kg, body temperature 36.9 °C, blood pressure 134/85 mmHg, pulse rate 108 beats/min, and respiratory rate 17 cycles/min. The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was grade 4. Breathing and heart sounds were normal. Upon an examination, erythema on the face; heliotrope rash; aphthous ulcer in the oral cavity; extensive edematous erythema in the neck extending to the chest, back, and belt line; nail-bed bleeding; and Gottron papule were observed (Fig. 2). Muscle grasping pain was noted in both upper arms and thighs. Muscle weakness in the proximal muscles of the upper and lower limbs was also observed, and the results of a manual muscle test of the bilateral pectoralis major muscles, deltoid muscle, triceps brachii, iliopectos, quadriceps muscle, and hamstrings were 4 of 5.

The serum levels of myogenic enzymes were elevated (aspartate transferase, 166 IU/L; lactate dehydrogenase, 486 IU/L; creatine kinase, 3,272 U/L; aldolase, 15.2 U/L; myoglobin, 1,854 ng/mL). The serum C-reactive protein levels (1.59 mg/dL) and blood sedimentation rate (71 mm/h) were elevated. The tumor marker levels were decreased compared with those at the time of the diagnosis (pro-GRP, 62.8 pg/mL; NSE, 30.9 ng/mL). Chest CT showed a marked reduction in the tumor size in the lung and mediastinal lymph node (Fig. 1b). Antinuclear antibodies were positive, with a titer of 1:640 in speckled and cytoplasmic patterns. Serum autoantibodies were evaluated according to immunoprecipitation and enzyme-linked immunosorbent assays, as described previously (5). Anti-TIF1γ/α, anti-Ro60, and anti-Ro52 antibodies were positive at the diagnosis of SCLC before the development of DM and chemoradiotherapy (Fig. 3). The levels of anti-TIF1γ/α antibodies increased by 2- to 6-fold after the onset of DM, whereas those of anti-Ro52 antibodies decreased (Fig. 3b). Antibodies to aminoacyl-
tRNA synthetases and -Mi-2 were negative. She was diagnosed with classic DM based on muscle weakness, elevated levels of muscle enzymes, and typical skin rash. In addition, CAM was diagnosed because of the evidence of SCLC with positive results for anti-TIF1γ antibody (6). Although anti-Ro60 and anti-Ro52 antibodies were positive, she did not have sicca symptoms of Sjögren’s syndrome.

High-dose corticosteroid therapy (prednisone 1 mg/kg body weight) was initiated for DM, resulting in only partial improvement in muscle and skin symptoms (Fig. 4). Her general condition and performance status did not improve because of complicating bacterial pneumonia, a worsened mental condition, and SCLC progression. Thus, additional systemic chemotherapy could not be administered, and she died five months after the diagnosis of SCLC at another hospital where she had been transferred for terminal care.

### Discussion

We herein report a rare case of CAM that developed after initial chemoradiotherapy for SCLC despite tumor reduction. Serum anti-TIF1γ antibody was detected when the diagnosis of SCLC was made before the treatment of cancer and the development of DM, and its levels increased over time.
In patients with CAM, the occurrence of DM/PM after the diagnosis of malignant tumors is not rare (2, 7-9). Indeed, one study reported that more than 30% of malignancies preceded the diagnosis of DM/PM (7). Regarding the association between the cancer and activity of DM/PM, successful treatment of cancer, typically removal of cancer by surgery, leads to an improvement of the activity of DM/PM, and the relapse of cancers usually lead to flare-up of DM/PM (10-13). Given previous findings, the present case appears to be a very rare one because CAM developed after a marked reduction in tumor size by chemoradiotherapy and anti-TIF1γ antibodies were detected in a patient with SCLC without any signs of DM/PM.

The mechanism through which CAM developed after initial chemoradiotherapy for SCLC despite tumor reduction with increased levels of TIF1γ antibody in our patient is unclear. Since TIF1 is a known tumor-suppressor gene, a mutation in TIF1 may have been the primary event, leading to the development of SCLC, with mutated TIF1 antigens inducing an autoimmune response (4). Abnormal proteins expressed by tumor tissues may lead to an immune response, and the expression of mutated antigens may lead to the production of specific autoantibodies, such as anti-p53 and RNA polymerase III antibodies (14, 15). Furthermore, a large amount of tumor antigens released during chemoradiotherapy might play a role in stimulating the immune system, accelerating the autoantibody production and the subsequent development of DM in the present case. However, our speculation cannot be definitively confirmed, and the development of DM in this case might simply be a natural course.

Another interesting point of this case is the detection of anti-TIF1γ antibody at the cancer diagnosis before the onset of DM. The detection of anti-TIF1γ antibody in patients with malignancy without DM has not been well documented; only three cases of borderline positivity of the antibody in breast cancer patients without rheumatic diseases have been reported (16). The present case suggests that the detection of anti-TIF1γ antibody in cancer patients may be a useful marker for predicting DM/PM onset. Of further note, the levels of anti-Ro52 antibodies decreased while those of anti-TIF1γ and anti-TIF1α increased by 2- to 6-fold during the development of DM (Fig. 3b). Some autoantibodies may share common mechanisms of regulation, although non-parallel changes in different specific autoantibodies have also been reported. The development of anti-U1RNP or ribosomal P antibodies and a reduction in anti-RNA helicase A antibody levels in SLE has been reported (17). Our data therefore suggest different mechanisms of regulation for anti-TIF1γ and anti-TIF1α antibodies and for anti-Ro52 autoantibodies.

In the present case, anti-TIF1γ and anti-TIF1α antibodies were both positive. Fujimoto et al. showed that anti-TIF1α antibody often coexists with anti-TIF1γ antibody (18). Another report demonstrated that anti-TIF1α antibody can be found in patients with anti-Mi-2 antibody but without anti-TIF1γ antibody. In the present case, anti-Mi-2 antibody was negative, and cases with both anti-TIF1γ and TIF1α antibodies developed cancer more frequently than those with only anti-TIF1α antibodies (19). However, the clinical significance of these antibodies in lung cancer patients is not well understood, and the accumulation of more cases is desired.

The prognosis of patients with CAM generally depends on the prognosis of cancer (20-23); therefore, the treatment of cancer is essential for CAM. Treatment with corticosteroids and/or immunosuppressants is considered when necessary. In a review of 12 patients with CAM with SCLC, a very poor prognosis of 2 weeks to 9 months (median: 5 weeks) was reported (24). Compared with the median survival of 9.4 to 12.8 months in patients with extensive-disease SCLC, the prognosis of SCLC patients with CAM may be worse than that in patients with SCLC without CAM (25). An inadequate response of myopathy to corticosteroid treatment in certain patients may limit the treatment options for cancer, as seen in our case, leading to a poor prognosis.

**Conclusion**

We herein report a rare case of SCLC with anti-TIF1γ antibody and the subsequent development of DM despite tumor reduction by systemic chemoradiotherapy along with an increase in the levels of anti-TIF1γ antibody. Anti-TIF1γ antibody is known to be a marker for CAM; however, the present case indicates that the antibody can be found in cancer patients without DM. It should be noted that CAM might be a poor prognostic factor for SCLC.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Trallero-Araguas E, Labrador-Horillo M, Selva-O’Callaghan A, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 89 : 47-52, 2010.
2. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64 : 523-532, 2012.
3. Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One 9 : e94128, 2014.
4. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52 : 1-19, 2017.
5. Satoh MCA, Hirakata M, Chan EKL. Immunodiagnosis of autoimmune myopathies. In: Manual of Molecular and Clinical Laboratory Immunology. Eighth ed. Detrick B HR, Schmitz JL, Eds. ASM press, Washington, DC., 2016: 878-887.
6. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84 : 231-249, 2005.
7. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326: 363-367, 1992.
8. Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 87: 299-308, 2016.
9. Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 52: 20-33, 2017.
10. Solomon SD, Maurer KH. Association of dermatomyositis and dysgerminoma in a 16-year-old patient. Arthritis Rheum 26: 572-573, 1983.
11. Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 180: 212-216, 1990.
12. Yoshinaga A, Hayashi T, Ishii N, Ohno R, Watanabe T, Yamada T. Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 12: 593-595, 2005.
13. Tallai B, Flasko T, Gyorgy T, et al. Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy. Clin Rheumatol 25: 119-120, 2006.
14. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
15. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343: 152-157, 2014.
16. Shah AA, Rosen A, Hummers LK, et al. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin Exp Rheumatol 35 (suppl 106): 71-74, 2017.
17. Yamasaki Y, Narain S, Yoshida H, et al. Autoantibodies to RNA helicase A: a new serologic marker of early lupus. Arthritis Rheum 56: 596-604, 2007.
18. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64: 513-522, 2012.
19. Muro Y, Ishikawa A, Sugura K, Akiyama M. Clinical features of anti-TIF1-alpha antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-gamma or anti-Mi-2 autoantibodies. Rheumatology (Oxford) 51: 1508-1513, 2012.
20. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22: 1300-1303, 1995.
21. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41: 729-734, 2002.
22. Ponyi A, Constantin T, Garami M, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 1051: 64-71, 2005.
23. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35: 438-444, 2008.
24. Lee WY, Kastelik J, Campbell A, Avery G, McGivern D, Lind M. A case report of dermatomyositis associated with small cell lung cancer. Tumori 98: 158e-161e, 2012.
25. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).